Hi @Jonboi11, I’m not sure that breakeven will be the first significant catalyst for the share price rising. I believe it will be the earlier off-take or revenue announcements.
While you never know the timing for sure, all of the right building blocks are in place. Higher value C-103 offtake has started this year and will expand over the next 12 months. Supply of titanium is now secure.
Amaero seems to have the right production team in place, as evidenced by accelerated qualification of C-103 powder. The next atomiser is due mid next year.
They also seem to have the right commercial outreach in place - the first submarine contract happened almost under the radar. And the US submarines themselves are committed to using more advanced manufacturing techniques, such as 3D printing and production of near net shapes. I believe this is going to expand rapidly and over the next immediate period of time.
A US election always slows things down. The old president is called a lame duck. And while the positioning for the next president can start, nothing gets signed during this period.
In terms of dilution, if you have a look at Hank’s past communications, you’ll see predictions of how much should be raised through equity and how much through non-dilutive funding, including debt and/or grants.
Net, I’m not sure we’ll hit Kenji’s aggressive targets before Xmas. But I really wouldn’t be surprised if more material offtake agreements for C-103 or Ti64 happen before the end of the first quarter of calendar year 2025.
Offtake revenue is key. And my best guess is that this happens well ahead of breakeven, and probably quite soon.
DYOR of course.
- Forums
- ASX - By Stock
- 3DA
- 3DA 2024 and beyond
3DA
amaero ltd
Add to My Watchlist
5.71%
!
37.0¢

3DA 2024 and beyond, page-342
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
37.0¢ |
Change
0.020(5.71%) |
Mkt cap ! $255.5M |
Open | High | Low | Value | Volume |
35.5¢ | 38.0¢ | 35.5¢ | $220.6K | 599.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4961 | 37.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
38.0¢ | 135653 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4961 | 0.370 |
1 | 25000 | 0.365 |
1 | 8000 | 0.355 |
2 | 80000 | 0.350 |
2 | 70000 | 0.320 |
Price($) | Vol. | No. |
---|---|---|
0.380 | 121653 | 2 |
0.385 | 5000 | 1 |
0.390 | 70588 | 2 |
0.395 | 11888 | 1 |
0.400 | 174214 | 6 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
3DA (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online